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Abstract 
Background: We aim to determine the prevalence of anemia in ACS patients and compared 
their clinical characteristics, management and clinical outcomes to those without anemia in 
an unselected national ACS cohort.  
Methods and Results: The Myocardial Ischemia National Audit Project (MINAP) registry 
collects data on all adults admitted to hospital trusts in England and Wales with diagnosis of 
an ACS. We conducted a retrospective cohort study by analyzing patients in this registry 
between January 2006 and December 2010 and followed them up until August 2011. 
Multiple logistic regressions were used to determine factors associated with anemia and the 
adjusted odds of 30-day mortality with 1 g/dl incremental hemoglobin increase and the 30-
days and 1-year mortality for anemic compared to non-anemic groups.  Analyses were adjusted 
for covariates.  Our analysis of 422,855 patients with ACS showed that 27.7% of patients 
presenting with ACS are anemic, and that these patients are older, have a greater prevalence 
renal disease, peripheral vascular disease, diabetes mellitus and previous acute myocardial 
infarction and are less likely to receive evidence based therapies shown to improve clinical 
outcomes. Finally our analysis suggests that anemia is independently associated with 30-day 
(OR 1.28, 95%CI 1.22-1.35) and 1-year mortality (OR 1.31, 95%CI 1.27-1.35) and we 
observed a reverse J-shaped relationship between hemoglobin levels and mortality outcomes.   
Conclusion: The prevalence of anemia in a contemporary national ACS cohort is clinically 
significant. Patients with anemia are older and multi-morbid, and less likely to receive 
evidence-based therapies shown to improve clinical outcomes with the presence of anemia 
independently associated mortality outcomes.  
Keywords: Acute coronary syndrome; anemia; mortality 
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List of abbreviations 
ACS=acute coronary syndrome 
CV=cardiovascular 
RCT=randomized controlled trials 
NHS=National Health Service 
STEMI=ST segment elevation myocardial infarction 
NSTEMI=non-ST segment elevation myocardial infarction 
ACE=angiotensin converting enzyme  
WHO=World Health Organization 
ATE=average treatment effects 
COPD=chronic obstructive pulmonary disease 
PCI=percutaneous coronary intervention 
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Introduction 
 Both registry data1-4 and secondary analyses of randomized controlled trials5-7 have 
suggested that the burden of anemia in patients presenting with acute coronary syndromes 
(ACS) is significant. A recent meta-analysis of 27 studies including 233,144 patients has 
reported a prevalence of anemia in ACS patients close to 20%8 and current clinical guidelines 
fail to offer firm recommendations for its concurrent management in the ACS setting.9,10 
 
 Patients with anemia are older3,6,7,11 with a significantly greater burden of co-
morbidities such as chronic kidney disease,12-14 diabetes,6,13,14 heart failure,13,15 more 
extensive coronary artery disease6 and are less likely to undergo cardiac catheterization.4,6,11 
These adverse clinical characteristics are well known to contribute to adverse outcomes in 
patients with ACS. Previous reports have suggested that ACS patients with anemia have 
significantly worse in-hospital and longer-term total and cardiac mortality outcomes,5-7,16,17 
heart failure,18 risk of major bleeding6 and of re-infarction.6,8,19 Some studies have reported 
that once differences in age or co-morbidity burden between anemic/non-anemic ACS 
cohorts are adjusted for; anemia is no longer an independent predictor of adverse mortality20 
or cardiovascular mortality21 whilst other studies report that the relationship persists.6,7,19,22 
Other studies have reported different relationships between anemia and cardiovascular (CV) 
outcomes according to sex, with baseline anemia independently associated with higher rates 
of all cause and cardiac mortality at 30-days and 1-year in men but not in women.7 
 
 Data derived from secondary analyses from randomized controlled trials (RCT) have 
suggested adverse mortality outcomes associated with anemia in patients with ACS,5,6,23 such 
RCTs often exclude older patients with the most severe co-morbid conditions and may 
therefore under-report the prevalence of anemia and under-estimate its prognostic impact. 
Many of the studies that have reported relationships between anemia and adverse outcomes in 
the setting of ACS, have not adjusted for/excluded patients with major bleeding events3,5,24 
that may further confound the relationships reported. 
 
 We have estimated the prevalence of anemia in ACS patients and compared their 
clinical characteristics, management and clinical outcomes to those without anemia in an 
unselected national ACS cohort derived from the Myocardial Ischaemia National Audit 
Project (MINAP) registry that collects data on all patients in the UK admitted with a 
confirmed diagnosis of ACS. We also examined the relationship between anemia and short 
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(30-day) and longer-term (1-year) mortality outcomes in this setting and assessed whether the 
prognostic impact of anemia relates to its severity.  
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Methods 
Study design and population 
 
 The Myocardial Ischemia National Audit Project (MINAP) registry collects data on 
all patients age 18 or over in the United Kingdom who are admitted to all 230 NHS hospital 
trusts in England and Wales with a confirmed diagnosis of an ACS. We analyzed data from 
the registry for patients admitted between January 2006 and December 2010 on this registry 
and followed them up until August 2011.   Participants were included in the current study if 
they had a diagnosis of any ACS (STEMI, NSTEMI or unstable angina) determined by the 
medical team at time of discharge.  Mortality outcome was ascertained by linkage through the 
Office of National Statistics.25  
 
Data collection 
 
 The MINAP dataset collects standardized data on pre-hospital and in-hospital care for 
all ACS admissions from all 230 NHS trusts in England and Wales and is part of the NHS 
data dictionary.[http://www.hqip.org.uk/minap-2013-report/]  The data is collected by nurses 
and clinical audit staff and contains 123 fields.  The details of development and initial 
findings are reported elsewhere.26  
 
 In the current study variables included in the analyses were hemoglobin at the time of 
admission with an ACS, age, sex, smoking status, peak troponin levels, hyperlipidemia, 
hypertension, prior angina, prior myocardial infarction, prior heart failure, prior stroke, 
peripheral vascular disease, chronic obstructive pulmonary disease, diabetes, renal failure, 
prior percutaneous coronary intervention, prior coronary artery bypass graft, prior 
medications (angiotensin converting enzyme (ACE) inhibitor, beta-blocker, statin, 
clopidogrel, aspirin), clinical diagnosis (unstable angina, NSTEMI, STEMI), discharge 
medications (ACE inhibitor, beta-blocker, statin, clopidogrel, aspirin), angiography, in-
hospital bleeding and mortality outcomes in-hospital, 30-days and 1-year.  World Health 
Organization (WHO) hemoglobin thresholds were used to define anemia as <13 g/dl for men 
and <12 g/dl for women. 
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Statistical analysis 
 
 Multiple imputations by chained equations in STATA version 13.0 was used to 
impute missing values for variables where possible.  We describe baseline variables 
according to whether they were missing or non-missing in tables and details of participant 
inclusion is shown graphically.  Descriptive statistics are presented for baseline variables and 
outcome according to anemia status and sex.  Associations between anemia status and 
individual variables were tested using one-way analysis of variance for continuous variables 
and Chi-squared test for categorical variables.  We used multiple logistic regression with 
adjustments for baseline variables to determine factors associated with anemia.  The same 
regression methods were used to determine the adjusted odds of 30-day mortality with 1 g/dl 
incremental hemoglobin increase from <10 g/dl to ≥18 g/dl for men and from <9 g/dl to ≥17 
g/dl for women.  These results were presented graphically.  Additional analyses were 
performed to determine the adjusted odds ratio of mortality at 30-days and 1-year for anemic 
compared to non-anemic group for the whole cohort, the male only cohort, female only 
cohort, NSTEMI cohort, STEMI cohort and subgroups where bleeding was excluded.  The 
baseline variables of the group of participants who bled and did not bleed were also 
compared.  Further analysis was performed restricting the cohort which had no imputations.  
Severity of anemia was examined by stratifying the cohort by sex specific hemoglobin 
cutoffs (Hb <10 g/dl, Hb 10-11 g/dl, Hb 11-12 g/dl, Hb 12-13 g/dl, Hb ≥13 g/dl for men and 
Hb <9 g/dl, Hb 9-10 g/dl, Hb 10-11 g/dl, Hb 11-12 g/dl, Hb ≥12 g/dl for women.  To better 
control for baseline differences across the anemic and non-anemic groups, further analysis 
was performed using propensity score matching (mi estimate:teffects psmatch) to estimate 
average treatment effects (ATE). Although multiple regression is the most widely used 
method to control for measured confounders, it can be inadequate when the two comparator 
groups (anaemia vs no anaemia in our analyses) are very different across key confounders. 
Propensity score matching can be a better approach in such extreme scenarios and can thus 
serve as a useful sensitivity analysis. Propensity scores were calculated using multiple 
logistic regression and then 1:1 matching with replacement (i.e. including all cases and 
controls) was performed prior to simple logistic regression models to obtain the ATE. 
Statistics to demonstrate the success of the matching are also reported. 
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Ethics approval  
 
 The current study obtained the ethical approval from the Faculty of Medicine & 
Health Sciences Research Ethics Committee, University of East Anglia. 
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Results 
 
 There were a total of 424,848 participants in the MINAP cohort between January 
2006 to December 2010 who were followed up till August 2011. Of them, hemoglobin values 
were recorded in 257,999 patients. Supplementary Figure 1 shows the flow diagram of 
participant inclusion and comparison of characteristics between those with and without 
available data on Hb did not show any material differences (Supplementary Table 1) 
 
 The prevalence of anemia in this cohort was 71,223/256,744 (27.7%). After multiple 
imputations the sample size of the complete dataset with all imputed variables was 256,744.   
 
 The descriptive statistics of baseline variables the included cohort by anemia status is 
shown in Table 1.  The anemic cohort was significantly older with a higher proportion of 
smokers (85% vs 68%, p<0.001), prior hypertension (59% vs 48%, p<0.001), angina (43% vs 
27%, p<0.001), myocardial infarction (38% vs 23%, p<0.001), prior heart failure (12% vs 
4%, p<0.001), stroke (14% vs 7%, p<0.001), peripheral vascular disease (8% vs 3%, 
p<0.001), COPD (18% vs 14%, p<0.001), diabetes (31% vs 16%, p<0.001) and renal failure 
(19% vs 4%, p<0.001). Participants who were anemic were more likely to have aspirin and 
clopidogrel prior to admission (7% vs 5%, p<0.001) and less likely to be prescribed dual-
antiplatelet therapy on discharge (75% vs 79%, p<0.001).  Participants whose anemia 
occurred in the context of a bleeding complication were more likely to be female, be on 
aspirin before admission and on discharge (30% vs 28%, p<0.001), have STEMI diagnosis 
(52% vs 38%, p<0.001), less likely to receive angiography (26% vs 38%, p<0.001) and more 
likely die at 30 days (6% vs 3%, p<0.001) and 1 year (12% vs 8%, p<0.001) (Supplementary 
Table 2).Similar rates of angiography were performed in the anemic vs. non-anemic cohort 
but patients with anemia were significantly less likely to be prescribed secondary prevention 
medications post discharge. The difference in crude mortality rates between the anemic and 
non-anemic groups increased with longer follow up. 
  
Multiple logistic regression where used to determine the independent factors 
associated with the presence of anemia at baseline (Table 2).  The most significant 
associations were observed with presence of peripheral vascular disease (OR 1.427 95% CI 
1.362-1.496, p<0.001), diabetes mellitus (OR 1.786 95% CI 1.742-1.832, p<0.001) and renal 
disease (OR 3.058 95% CI 2.962-3.158, p<0.001). 
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The adjusted odds of mortality by incremental (1 g/dl) increase in hemoglobin is 
shown in Figure 1. Lower hemoglobin values were associated with significantly higher 
mortality with a non-significant trend towards higher mortality in those patients with elevated 
hemoglobin values. 
  
The odds of mortality associated with the presence of anemia following adjustment 
for baseline co-variates is shown in Table 3. We observed that there was a ~1.3 fold increase 
in odds of 30-day mortality (OR 1.281 95% CI 1.217-1.350, p<0.001) and 1-year (OR 1.311 
95% CI 1.274-1.348, p<0.001) mortality respectively with anemia after adjustment for 
potential confounders. Similar significant increases in mortality with anemia were observed 
for men (30 day mortality OR 1.298 95% CI 1.217-1.384, p<0.001. 1 year mortality OR 
1.354 95%CI 1.299-1.411, p<0.001) and women (30 day mortality OR 1.255 95% CI 1.146-
1.374, p<0.001, 1 year mortality OR 1.252 95% CI 1.198-1.309, p<0.001) as well as 
diagnosis of NSTEMI (30 day mortality OR 1.291 95% CI 1.213-1.374, p<0.001, 1 year 
mortality OR 1.326 95% CI 1.281-1.374, p<0.001) and STEMI (30 day mortality 1.269 95% 
CI 1.163-1.384, p<0.001, 1 year mortality OR 1.284 95% CI 1.284-1.352, p<0.001). In order 
to eliminate the potential confounding influence of major bleeding complications on the 
relationship between anemia and mortality, we repeated the analysis following exclusion of 
patients with major bleeding complications and similar results were recorded (30 day 
mortality OR 1.279 95% CI 1.213-1.348, p<0.001, 1 year mortality OR 1.309 95% CI 1.271-
1.347, p<0.001). Furthermore, a sensitivity analysis was undertaken in patients in whom Hb 
values were recorded at baseline (257,999 patients) and similar independent factors 
associated with anemia (Supplementary Table 3) and mortality outcomes associated with 
anemia (Supplementary Table 4) were observed. 
 
 Propensity score matched analysis is shown in Table 4 and anemia is associated with 
significant increase in mortality at both 30 days and 1 year after adjustments for propensity 
score (30 day mortality coefficient 0.0080 95% CI 0.0045-0.0114, p<0.001, 1 year mortality 
coefficient 0.0173 95% CI 0.0128-0.0218, p<0.001). 
 
There were also differences in baseline characteristics according to sex (Table 5).  
Most notably, females were younger (mean age 74 vs 67 years, p<0.001) but more were 
smokers (79% vs 70%, p<0.001) and hypertensive (56% vs 47%, p<0.001).  However 
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medication at discharge was higher in men and women had a higher proportion of patient 
with adverse outcomes. 
 
 The sex specific adjusted odds of mortality by incremental (1 g/dl) increase in 
hemoglobin is shown in Figure 2. For both sexes, lower hemoglobin values were associated 
with significantly higher mortality but high values of hemoglobin were only associated with 
higher mortality in men but not women.  Similar results were observed if patients with 
bleeding were excluded (Supplementary Figure 2). 
 
 In terms of severity of anemia there was a increase in mortality at both 30 days and 1 
year with reduced hemoglobin which ranged from ~1.2-1.3 fold increase in odds of mortality 
for Hb 12-13 g/dl to ~1.4-1.5 fold increase for Hb <10 g/dl for men (Table 6).  For women, 
similar results were recorded. 
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Discussion  
 Our analysis is the largest analysis to study the prevalence, clinical characteristics and 
outcomes associated with anemia in an unselected national cohort of ACS patients in the 
United Kingdom. We have observed that more than to one in four patients presenting with 
ACS are anemic, and that these patients are older, have a greater prevalence of co-morbid 
conditions and are less likely to receive evidence based therapies shown to improve clinical 
outcomes. Finally our analysis suggests that anemia is independently associated with adverse 
in-hospital and longer-term mortality outcomes, with a reverse J-shaped relationship between 
Hb levels and both short and longer mortality outcomes observed.   
 
 Our observed prevalence of anemia of 28% is greater than that reported in data 
derived from RCTs reporting rates of between 10-25%5-7,23 although registry data reveals 
significantly higher prevalences.4,12,27 For example, an analysis of 78,974 Medicare 
beneficiaries aged 65 years or older hospitalized with acute myocardial infarction revealed a 
prevalence of anemia of 43%.12 We have observed that ACS patients with anemia are older, 
have a greater prevalence of co-morbid conditions and are less likely to receive evidence 
based therapies for the treatment of ACS in agreement with previous literature.5-7,19,21 
 
 In the current analysis, we report that the presence of anemia is independently 
associated with an approximately 50% increased risk of mortality in the short and long-term, 
and that this prognostic impact is observed in both men and women, in contrast to the 
findings of a secondary analysis of the HORIZONS-AMI trial that failed to demonstrate an 
association between anemia and increased risk of mortality in women.7 We have observed a 
reverse J-shaped relationship between decreasing Hb values and 30-day mortality, with a 
dose-response effect with progressively lower odds of survival with more profound degrees 
of anemia in both men and women. Similar reverse j-shaped relationships between Hb levels 
and CV death and CV death, myocardial infarction or recurrent ischemic events in some 
studies,21 whilst other studies have not revealed such statistically significant relationships in 
either in-hospital cardiac mortality16 or longer term mortality.1  
 
 Previous studies have reported that anemia is independently associated with adverse 
clinical outcomes, many of these studies did not report whether patients with bleeding events 
were excluded from their analyses as it is well documented that major bleeding is 
independently associated with mortality in the ACS setting28-30 which might have confounded 
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any reported relationships between the presence of anemia and mortality. In the current 
analysis, we report anemia independently predicts adverse mortality outcomes and that the J-
shaped relationship between Hb level and mortality persists even after exclusion of patients 
with bleeding events.  
 
 There are several biological and clinical reasons why anemia may lead to worse 
clinical outcomes in patients with ACS. In the setting of ACS, anemia might worsen 
ischaemia by decreasing the oxygen delivery to the jeopardized myocardium and increase 
myocardial oxygen demand due to greater cardiac output to maintain adequate systemic 
oxygen delivery.31,32 Clinically, patients with anemia are often under-prescribed antiplatelet 
therapy due to bleeding concerns, for example in our current analysis clopidogrel was 
prescribed in 73% of patients without anemia and 66% with anemia (P<0.001) whilst in the 
CADILLAC trial 18% of patients with anemia at the time of their ACS were no longer 
receiving aspirin at 1 year,23 which might contribute to increased cardiovascular events. 
Analysis of the ACUITY trial suggests that patients with anemia were less likely to undergo 
percutaneous coronary intervention (PCI) and more likely to be medically managed which 
may further contribute to worse cardiovascular outcomes in this group.6 Finally anemia may 
be a manifestation of numerous chronic disease states and the presence of anemia is merely a 
marker of poorer outcomes in patients with chronic diseases.  
 Our analysis suggests that anemia is independently associated with adverse clinical 
outcomes in patients presenting with ACS, there is a lack of clarity in contemporary guideline 
recommendations as to whether such patients with anemia should be transfused and the 
optimal transfusion strategy.33 The American Association of Blood Banks recommendation 
for patients presenting with ACS is “No recommendation for or against a liberal or restrictive 
transfusion threshold for hospitalized, hemodynamically stable patients with acute coronary 
syndrome.”33  Furthermore, the CRIT (conservative versus liberal red cell transfusion in acute 
myocardial infarction) randomized pilot trial34 demonstrated that patients with ACS and a 
hematocrit level <30% who were randomized to a liberal transfusion arm had a significantly 
higher composite endpoint of in-hospital death, recurrent myocardial infarction, or congestive 
heart failure than those who underwent more restrictive transfusion practice (38% vs. 13%; p 
= 0.046). In contrast, in the MINT (A Multicenter, Randomized Study of Argatroban Versus 
heparin as Adjunct to Tissue Plasminogen Activator [TPA] in Acute Myocardial Infarction: 
Myocardial Infarction With Novastan and TPA) pilot study undertaken in 110 patients 
presenting with an ACS or stable angina with anemia undergoing cardiac catheterization, 
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patients randomized to a liberal blood transfusion strategy had 50% lower primary outcome 
rates of death, myocardial infarction, and unscheduled revascularization compared to those 
patients randomized to a restrictive transfusion strategy, with lower 30-day mortality too. A 
recent meta-analysis of 10 studies consisting mainly of registry studies including 203,665 
patients has shown a close to 3-fold independent increase in the risk of mortality associated 
with a liberal blood transfusion strategy in the AMI setting with meta-regression adjusting for 
a history of bleeding or baseline hemoglobin level revealing a similar increased risk, 
indicating a significant risk for blood transfusion over and above that associated with 
bleeding or anemia35 with similar findings reported in the PCI setting.36  
 
 Our study has some limitations. The MINAP dataset requires the recording of Hb 
within 24 hours of admission, many of these Hb values particularly in the setting of 
hemodynamically unstable NSTEMI or STEMI treated with primary PCImay be post PCI and 
may reflect the influence of acute bleeding complications and not reflect chronic anemia. 
Nevertheless, even following exclusion of patients who sustained bleeding complications 
during their in-hospital course, the relationships that we examined remained unchanged. We 
report an association between anemia and in-hospital and longer-term mortality, we cannot 
infer causality. While it would be interesting to know whether anemia was associated with 
cardiac mortality, we were unable to determine the cause of death for participants. We have 
adjusted for differences in baseline characteristics between the anemic/non-anemic cohorts, 
other unmeasured confounders may be contributing to the adverse clinical outcomes 
associated with anemia that we report. Another limitation was the missing data, which varied 
extent depending on the study variable, and we tried to approximate these values using 
multiple imputations to impute the missing values. Finally, the MINAP dataset does not 
record the receipt of blood transfusions which may contribute to the adverse clinical 
outcomes reported.35 
 
Conclusions 
 
 In conclusion, this is the largest to study the prevalence, clinical characteristics and 
outcomes associated with anemia in an unselected national cohort of ACS patients in the 
United Kingdom. We report a significant prevalence of anemia in a contemporary ACS 
cohort, with approximately one in four patients presenting with ACS being anemic, and that 
these patients are older, have a greater prevalence of co-morbid conditions and are less likely 
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to receive evidence based therapies shown to improve clinical outcomes. Finally our findings 
suggest that anemia is independently associated with adverse 30-day and longer-term 
mortality outcomes, with a reverse J-shaped relationship between Hb levels and mortality 
outcomes observed in both men and women. The clinical effectiveness of correcting anemia 
routinely in ACS has not been widely explored, there is considerable uncertainty in the value 
of such an approach. Targeted intervention strategies in this patient population should be 
explored. 
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Table 1: Baseline characteristic of the MINAP cohort according to anemia status  
 
Variable†‡ No anemia 
(n=185,521) 
Anemia (n=71,223) p-value‡ 
Mean age (years) 66 (±14) 76 (±12) <0.001 
Male (%) 124,143/185,521 (67%) 44,027/71,223 (62%) <0.001 
Current or ex-smokers 118,634/174,003 (68%) 54,361/64,210 (85%) <0.001 
Peak troponin 
Median Troponin I (IQR) (µg/L) 
Median Troponin T (IQR) (µg/L) 
Mean Troponin I (SD) (µg/L) 
Mean Troponin T (SD) (µg/L) 
 
1.1 (0.2-7.1) 
1.2 (0.2-7.4) 
10 (±24) 
10 (±22) 
 
1.0 (0.2-5.3) 
1.0 (0.2-5.6) 
9 (±22) 
8 (±20) 
NA 
 
 
Comorbidities  
Hyperlipidemia 62,060/113,535 (35%) 24,442/67,499 (36%) <0.001 
Hypertension 86,052/180,2044 (48%) 40,573/69,230 (59%) <0.001 
Prior angina 47,915/179,636 (27%) 29,629/68,890 (43%) <0.001 
Prior myocardial infarction 41,215/180,166 (23%) 26,028/69,119 (38%) <0.001 
Prior heart failure 7,286/177,567 (4%) 7,870/68,411 (12%) <0.001 
Stroke 12,320/177,656 (7%) 9,337/68,636 (14%) <0.001 
PVD 5,852/171,572 (3%) 5,019/66,849 (8%) <0.001 
COPD 24,625/173,811 (14%) 12,489/67,813 (18%) <0.001 
Diabetes 29,016/180,989 (16%) 21,915/69,594 (31%) <0.001 
Renal failure 7,025/177,840 (4%) 13,283/68,831 (19%) <0.001 
Prior PCI 18,865/179,306 (11%) 8,354/68,560 (12%) <0.001 
Prior CABG 10,522/179,580 (6%) 6,858/68,799 (10%) <0.001 
Medications prior to admission  
ACE inhibitor 59,891/171,542 (35%) 31,984/66,325 (48%) <0.001 
Beta blocker 49,387/171,865 (29%) 25,446/66,413 (38%) <0.001 
Statin 71,339/173,840 (41%) 37,842/66,978 (57%) <0.001 
Clopidogrel 13,506/81,575 (17%) 6,782/29,402 (23%) <0.001 
Aspirin 46,856/167,055 (28%) 18,593/64,237 (29%) <0.001 
Aspirin and clopidogrel 3,490/72,682 (5%) 1,814/26,198 (7%) <0.001 
Diagnosis at current admission <0.001 
NSTEMI or unstable angina 104,928/170,135 (62%) 41,049/65,285 (63%)  
STEMI 65,207/170,135 (38%) 24,235/65,285 (37%)  
Medications at discharge  
ACE inhibitor 121,885/185,521 (66%) 39,458/71,223 (55%) <0.001 
Beta blocker 117,353/185,521 (63%) 38,709/71,223 (54%) <0.001 
Statin 136,696/185,521 (74%) 47,976/71,223 (67%) <0.001 
Clopidogrel  56,980/64,186 (89%)  17,381/20,595 (84%) <0.001 
Aspirin 129,872/145,076 (90%) 49,657/55,517 (89%) 0.623 
Aspirin and clopidogrel 39,445/50,208 (79%) 12,065/16,098 (75%) <0.001 
Angiography performed  
Angiography 70,914/185,521 (38%) 27,034/71,223 (38%) 0.319 
Mortality outcomes    
Mortality at 30 days 3,425/184,228 (2%) 3,691/70,771 (5%) <0.001 
Mortality at 1 year 8,520/183,041 (5%) 9,173/70,339 (13%) <0.001 
Bleeding Outcomes    
In-hospital bleeding 3,475/174,183 (2%) 1,337/67,023 (2%) 0.998 
  22 
† Results reported as mean (SD) for continuous variables and n (%) for categorical variables.  
‡ Logistic regression (continuous variables), Chi2 square test (categorical variables). 
BMI=body mass index, COPD=chronic obstructive pulmonary disease, PVD=peripheral 
vascular disease, PCI=percutaneous coronary intervention, CABG=coronary artery bypass 
graft 
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Table 2: Significant factors associated with anemia (n=422,855): logistic regression model* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*All covariates in the table were included in the multiple logistic regression. 
Variable† Odds Ratio (95% CI) p-value ‡ 
Age 1.046 (1.045-1.046) <0.001 
Male sex 1.108 (1.088-1.128) <0.001 
Smoker 1.243 (1.216-1.271) <0.001 
Hypercholesterolemia 0.896 (0.876-0.916) <0.001 
Angina 1.208 (1.182-1.235) <0.001 
Previous myocardial infarction 1.208 (1.182-1.235) <0.001 
Previous heart failure 1.242 (1.192-1.293) <0.001 
Previous stroke 1.191 (1.153-1.230) <0.001 
Peripheral vascular disease 1.427 (1.362-1.496) <0.001 
Chronic obstructive pulmonary 
disease 
1.109 (1.083-1.136) <0.001 
Diabetes mellitus 1.786 (1.742-1.832) <0.001 
Renal disease 3.058 (2.962-3.158) <0.001 
Previous percutaneous coronary 
intervention 
0.967 (0.935-1.000) 0.05 
Previous coronary artery bypass 
graft 
1.074 (1.040-1.110) <0.001 
Admission medication 
Clopidogrel 
Aspirin 
 
1.223 (1.186-1.262) 
1.024 (1.004-1.045) 
 
<0.001 
<0.001 
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Table 3: Multivariate association between anemia and mortality: logistic regression models 
 
Total cohort 
Mortality outcome N Odds ratio (95% CI) p-value 
Mortality at 30 days 420,614 1.281 (1.217-1.350) <0.001 
Mortality at 1 year 418,471 1.311 (1.274-1.348) <0.001 
Men only 
Mortality at 30 days 274,278 1.298 (1.217-1.384) <0.001 
Mortality at 1 year 272,812 1.354 (1.299-1.411) <0.001 
Women only 
Mortality at 30 days 146,336 1.255 (1.146-1.374) <0.001 
Mortality at 1 year 145,659 1.252 (1.198-1.309) <0.001 
NSTEMI 
Mortality at 30 days 260,446 1.291 (1.213-1.374) <0.001 
Mortality at 1 year 259,003 1.326 (1.281-1.374) <0.001 
STEMI 
Mortality at 30 days 159,962 1.269 (1.163-1.384) <0.001 
Mortality at 1 year 159,265 1.284 (1.220-1.352) <0.001 
 
Bleeding excluded 
Mortality outcome N Odds ratio (95% CI) p-value 
Mortality at 30 days 412,396 1.279 (1.213-1.348) <0.001 
Mortality at 1 year 410,301 1.309 (1.271-1.347) <0.001 
Men only 
Mortality at 30 days 268,985 1.293 (1.209-1.381) <0.001 
Mortality at 1 year 267,547  1.348 (1.294-1.405) <0.001 
Women only 
Mortality at 30 days 143,378 1.255 (1.150-1.371) <0.001 
Mortality at 1 year 142,720 1.253 (1.198-1.310) <0.001 
  
Total cohort without imputations 
Mortality outcome N Odds ratio (95% CI) p-value 
Mortality at 30 days 
Unadjusted  
Fully adjusted 
 
254,999 
34,861 
 
2.905 (2.770-3.045) 
1.472 (1.197-1.810) 
 
<0.001 
<0.001 
Mortality at 1 year 
Unadjusted  
Fully adjusted 
 
253,380 
34,731 
 
3.072 (2.978-3.168) 
1.588 (1.430-1.763) 
 
<0.001 
<0.001 
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Table 4: Propensity score matching analysis on 10 imputed datasets, reporting average 
treatment effects (ATE). 
 
Analysis of propensity score matching with ATE 
 
Outcome N Coefficient 95% CI p-value 
30 day mortality 121,979 0.0080 0.0045 0.0114 <0.001 
1 year mortality  121.276 0.0173 0.0128 0.0218 <0.001 
 
Propensity score matching statistics 
 
Group Mean (SD) Median (IQR) 
Case (anemia) 0.739 (0.174) 0.782 (0.642, 0.875) 
Control (no anemia) 0.739 (0.174) 0.782 (0.642, 0.875) 
Abs (Case-Control) 0.00001 (0.00011) 7*10-6 (2*10-6, 0.00002) 
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Table 5: Baseline characteristic of the MINAP cohort in a single imputed dataset according 
to sex 
 
Variable†‡ Female (n=147,064) Male (n=275,791) p-value‡ 
Mean age (years) 74 (±13) 67 (±14) <0.001 
Current or ex-smokers 103,049/131,067 (79%) 175,401/251,888 (70%) <0.001 
Peak troponin 
Median Troponin I (IQR) (µg/L) 
Median Troponin T (IQR) (µg/L) 
Mean Troponin I (SD) (µg/L) 
Mean Troponin T (SD) (µg/L) 
 
0.8 (0.2-4.4) 
0.8 (0.1-5.6) 
7 (±20) 
7 (±18) 
 
1.1 (0.2-7.0) 
1.3 (0.2-9.4) 
10 (±23) 
10 (±22) 
NA 
 
 
Comorbidities  
Hyperlipidemia 45,444/132,621 (34%) 88,884/247,578 (36%) <0.001 
Hypertension 77,462/137,388 (56%) 120,727/255,434 (47%) <0.001 
Prior angina 45,397/136,047 (33%) 79,718/253,809 (31%) <0.001 
Prior myocardial infarction 35,001/137,514 (25%) 72,795/256,934 (28%) <0.001 
Prior heart failure 10,623/133,845 (8%) 13,559/248,960 (5%) <0.001 
Stroke 13,854/133,862 (10%) 20,079/248,892 (8%) <0.001 
PVD 5,448/130,925 (4%) 12,219/243,539 (5%) <0.001 
COPD 23,962/131,774 (18%) 34,462/244,671 (14%) <0.001 
Diabetes 29,493/140,481 (21%) 51,424/262,468 (20%) <0.001 
Renal failure 9,795/134,079 (7%) 17,931/249,319 (7%) 0.196 
Prior PCI 10,595/134,947 (8%) 30,254/251,990 (12%) <0.001 
Prior CABG 5,706/135,286 (4%) 20,933/252,728 (8%) <0.001 
Medications prior to admission  
ACE inhibitor 49,929/126,128 (40%) 88,256/234,196 (38%) <0.001 
Beta blocker 41,213/126,289 (33%) 73,726/234,423 (31%) <0.001 
Statin 58,420/129,601 (45%) 110,898/241,129 (46%) <0.001 
Clopidogrel 15,230/77,245 (20%) 28,564/142,840 (20%) 0.115 
Aspirin 37,535/131,780 (28%) 71,002/247,098 (29%) 0.103 
Diagnosis at current admission 0.143 
NSTEMI or unstable angina 83,404/134,524 (62%) 155,880/252,401 (62%)  
STEMI 51,120/134,524 (38%) 96,521/252,401 (38%)  
Medications at discharge  
ACE inhibitor 83,277/147,064 (57%) 171,311/275,791 (62%) <0.001 
Beta blocker 80,221/147,064 (55%) 165,753/275,791 (60%) <0.001 
Statin 99,246/147,064 (67%) 196,756/275,791 (71%) <0.001 
Clopidogrel 48,406/60,264 (80%) 98,181/115,628 (85%) <0.001 
Aspirin 102,340/114,611 (89%) 192,059/215,135 (89%) 0.862 
Angiography performed  
Angiography 55,049/147,064 (37%) 103,267/275,791 (37%) 0.939 
Mortality outcomes    
Mortality at 30 days 5,711/146,336 (4%) 7,474/274,278 (3%) <0.001 
Mortality at 1 year 14,149/145,659 (10%) 18,481/272,812 (7%) <0.001 
In-hospital bleeding 2,766/137,132 (2%) 4,932/257,591 (2%) 0.027 
† Results reported as mean (SD) for continuous variables and n (%) for categorical variables.  
‡ Logistic regression (continuous variables), Chi2 square test (categorical variables). 
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BMI=body mass index, COPD=chronic obstructive pulmonary disease, PVD=peripheral 
vascular disease, PCI=percutaneous coronary intervention, CABG=coronary artery bypass 
graft 
  28 
Table 6: Evaluation of the severity of anemia by sex using multiple logistic regression 
 
Outcome for 
men 
Hemoglobin 
≥13  
Hemoglobin 
12-13  
Hemoglobin 
11-12 
Hemoglobin 
10-11 
Hemoglobin 
<10 
Crude rate of 
mortality at 
30 days 
5,270/230,54
0 (2%) 
666/18,252 
(4%) 
589/10,918 
(5%) 
458/7,318 
(6%) 
491/7,250 
(7%) 
Adjusted 
odds of 
mortality at 
30 days 
1.00 
(reference) 
1.21 (1.10-
1.32), 
p<0.001 
1.35 (1.23-
1.48) , 
p<0.001 
1.38 (1.23-
1.54) , 
p<0.001 
1.38 (1.24-
1.54) , 
p<0.001 
Crude rate of 
mortality at 1 
year 
12,967/229,3
47 (6%) 
1,703/18,135 
(9%) 
1,440/10,844 
(13%) 
1,129/7,276 
(16%) 
1,242/7,210 
(17%) 
Adjusted 
odds of 
mortality at 1 
year 
1.00 
(reference) 
1.25 (1.18-
1.33) , 
p<0.001 
1.39 (1.31-
1.48) , 
p<0.001 
1.42 (1.32-
1.53) , 
p<0.001 
1.52 (1.42-
1.63) , 
p<0.001 
Outcome for 
women 
Hemoglobin 
≥12  
Hemoglobin 
11-12  
Hemoglobin 
10-11 
Hemoglobin 
9-10 
Hemoglobin 
<9 
Crude rate of 
mortality at 
30 days 
4,224/119,30
3 (4%) 
550/12,595 
(4%) 
481/7,882 
(6%) 
282/3,869 
(7%) 
174/2,687 
(6%) 
Adjusted 
odds of 
mortality at 
30 days 
1.00 
(reference) 
1.17 (1.05-
1.30), 
p=0.006 
1.33 (1.19-
1.48) , 
p<0.001 
1.38 (1.22-
1.56) , 
p<0.001 
1.24 (1.04-
1.47), 
p=0.015 
Crude rate of 
mortality at 1 
year 
10,490/118,7
85 (9%) 
1,387/12,522 
(11%) 
1,140/7,842 
(15%) 
672/3,839 
(18%) 
460/2,671 
(17%) 
Adjusted 
odds of 
mortality at 1 
year 
1.00 
(reference) 
1.17 (1.11-
1.24) , 
p<0.001 
1.29 (1.20-
1.38) , 
p<0.001 
1.37 (1.26-
1.50) , 
p<0.001 
1.34 (1.20-
1.50) , 
p<0.001 
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Figure 1: Adjusted odds of mortality at 30 days according to hemoglobin levels for men and 
women 
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Figure 2A & 2B: Adjusted odds of mortality at 30 days according to hemoglobin levels and 
sex 
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Table S1. Comparison of patients with missing and no missing hemoglobin values 
 
Variable†‡ No missing 
hemoglobin 
Missing hemoglobin 
Mean age (years) 69 (±14) 69 (±14) 
Male (%) 168,740/257,729 (65%) 107,805/166,421 (65%) 
Current or ex-smokers 173,966/239,409 (73%) 105,886/145,331 (73%) 
Peak troponin 
Median Troponin I (IQR) (µg/L) 
Median Troponin T (IQR) (µg/L) 
Mean Troponin I (SD) (µg/L) 
Mean Troponin T (SD) (µg/L) 
 
1.0 (0.2-6.5) 
1.1 (0.2-6.8) 
9.8 (±23.1) 
9.5 (±21.6) 
 
0.8 (0.1-4.6) 
0.8 (0.1-4.6) 
7.7 (±19.3) 
7.4 (±18.0) 
Comorbidities 
Hyperlipidemia 87,055/244,307 (36%) 48,030/137,680 (35%) 
Hypertension 127,321/250,699 (51%) 71,853/143,951 (50%) 
Prior angina 78,124/249,745 (31%) 47,790/141,926 (34%) 
Prior myocardial infarction 67,678/250,509 (27%) 40,725/145,773 (28%) 
Prior heart failure 15,263/247,189 (6%) 9,062/137,413 (7%) 
Stroke 21,784/247,508 (9%) 12,319/137,040 (9%) 
PVD 10,930/239,608 (5%) 6,821/136,614 (5%) 
COPD 37,359/242,828 (15%) 21,415/135,394 (16%) 
Renal failure 20,415/247,885 (8%) 7,453/137,312 (5%) 
Diabetes 51,220/251,808 (20%) 30,126/153,004 (20%) 
Prior PCI 27,391/249,078 (11%) 13,690/139,651 (10%) 
Prior CABG 17,520/249,593 (7%) 9,294/140,217 (7%) 
Medications prior to admission 
ACE inhibitor 92,430/239,043 (39%) 46,515/122,997 (38%) 
Beta blocker 75,333/239,462 (31%) 40,288/122,972 (33%) 
Statin 109,882/242,011 (45%) 60,424/130,487 (46%) 
Clopidogrel 20,493/111,931 (18%) 23,615/109,612 (22%) 
Aspirin 65,746/232,428 (28%) 43,268/148,246 (29%) 
Diagnosis at current admission 
NSTEMI or unstable angina 146,689 (62%) 93,749 (62%) 
STEMI 89,881 (38%) 58,441 (38%) 
Medications at discharge 
ACE inhibitor 162,012/257,999 (63%) 93,586/166,849 (56%) 
Beta blocker 156,807/257,999 (61%) 90,242/166,849 (54%) 
Statin 185,606/257,999 (72%) 111,758/166,849 (67%) 
Clopidogrel 74,777/85,595 (87%) 72,487/91,533 (79%) 
Aspirin 180,410/201,559 (90%) 115,392/129,727 (89%) 
Angiography performed 
Angiography 98,344/257,999 (38%) 60,770/166,849 (36%) 
Adverse outcomes   
Mortality at 30 days 7,147/256,244 (3%) 6,089/166,347 (4%) 
Mortality at 1 year 17,777/254,614 (7%) 15,004/165,816 (9%) 
In-hospital bleeding 4,833/242,369 (2%) 2,899/154,200 (2%) 
† Results reported as mean (SD) for continuous variables and n (%) for categorical variables. 
BMI=body mass index, COPD=chronic obstructive pulmonary disease, PVD=peripheral 
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vascular disease, PCI=percutaneous coronary intervention, CABG=coronary artery bypass 
graft 
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Table S2. Baseline characteristic of the MINAP cohort according to bleeding status  
 
Variable†‡ No bleed (n=387,025) Bleed (n=7,698) p-value‡ 
Mean age (years) 69 (±14) 69 (±14) 0.49 
Male (%) 252,659/387,025 (65%) 4,932/7,698 (64%) 0.027 
Current or ex-smokers 255,007/350,600 (73%) 5,070/6,967 (73%) 0.95 
Peak troponin 
Median Troponin I (IQR) (µg/L) 
Median Troponin T (IQR) (µg/L) 
Mean Troponin I (SD) (µg/L) 
Mean Troponin T (SD) (µg/L) 
 
0.9 (0.2-5.7) 
1.0 (0.2-6.0) 
9 (±22) 
9 (±20) 
 
0.9 (0.2-6.2) 
1.1 (0.2-6.7) 
9 (±22) 
9 (±22) 
NA 
 
 
Comorbidities  
Hyperlipidemia 122,875/348,013 (35%) 2,521/6,929 (36%) 0.064 
Hypertension 181,448/359,503 (50%) 3,678/7,140 (52%) 0.082 
Prior angina 114,293/356,737 (32%) 2,261/7,111 (32%) 0.66 
Prior myocardial infarction 98,633/360,908 (27%) 1,930/7,172 (27%) 0.43 
Prior heart failure 22,106/350,347 (6%) 445/7,015 (6%) 0.91 
Stroke 31,051/350,336 (9%) 616/7,008 (9%) 0.83 
PVD 16,155/342,771 (5%) 327/6,849 (5%) 0.81 
COPD 53,567/344,689 (16%) 1,061/6,873 (15%) 0.82 
Diabetes 74,123/368,835 (20%) 1,479/7,326 (20%) 0.85 
Renal failure 25,446/350,922 (7%) 551/7,006 (8%) 0.050 
Prior PCI 37,473/354,160 (11%) 777/7,032 (11%) 0.21 
Prior CABG 24,400/355,121 (7%) 525/7,063 (7%) 0.065 
Medications prior to admission  
ACE inhibitor 126,548/329,866 (38%) 2,569/6,622 (39%) 0.48 
Beta blocker 105,134/330,237 (32%) 2,147/6,623 (32%) 0.32 
Statin 154,984/339,574 (46%) 3,123/6,813 (46%) 0.75 
Clopidogrel 39,264/198,190 (20%) 736/3,896 (19%) 0.11 
Aspirin 99,895/351,685 (28%) 2,166/7,166 (30%) 0.001 
Diagnosis at current admission <0.001 
NSTEMI or unstable angina 223,184/358,532 (62%) 3,536/7,302 (48%)  
STEMI 135,348/358,532 (38%) 3,766/7,302 (52%)  
Medications at discharge  
ACE inhibitor 223,296/387,025 (60%) 4,645/7,698 (60%) 0.91 
Beta blocker 225,456/387,025 (58%) 4,445/7,698 (58%) 0.37 
Statin 271,095/387,025 (70%) 5,405/7,698 (70%) 0.75 
Clopidogrel 132,016/158,384 (83%) 2,562/3,104 (83%) 0.23 
Aspirin 274,090/305,303 (90%) 4,230/5,631 (75%) <0.001 
Angiography performed  
Angiography 148,882/387,025 (38%) 2,039/7,698 (26%) <0.001 
Mortality outcomes    
Mortality at 30 days 11,711/384,955 (3%) 473/7,625 (6%) <0.001 
Mortality at 1 year 29,829/382,920 (8%) 889/7,578 (12%) <0.001 
† Results reported as mean (SD) for continuous variables and n (%) for categorical variables.  
‡ Logistic regression (continuous variables), Chi2 square test (categorical variables). 
BMI=body mass index, COPD=chronic obstructive pulmonary disease, PVD=peripheral 
vascular disease, PCI=percutaneous coronary intervention, CABG=coronary artery bypass 
graft 
  34 
Table S3. Significant multivariate predictors of anemia in patients in whom baseline 
hemoglobin values were recorded (n=256,744) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable† Odds Ratio (95% CI) p-value ‡ 
Age 1.053 (1.052-1.054) <0.001 
Male sex 1.153 (1.129-1.176) <0.001 
Smoker 1.229 (1.196-1.263) <0.001 
Hypercholesterolemia 0.880 (0.861-0.991) <0.001 
Angina 1.048 (1.026-1.070) <0.001 
Previous myocardial infarction 1.214 (1.184-1.244) <0.001 
Previous heart failure 1.257 (1.211-1.304) <0.001 
Previous stroke 1.209 (1.171-1.247) <0.001 
Peripheral vascular disease 1.430 (1.367-1.496) <0.001 
Chronic obstructive pulmonary 
disease 
1.151 (1.121-1.181) <0.001 
Diabetes mellitus 1.942 (1.898-1.987) <0.001 
Renal disease 3.213 (3.107-3.323) <0.001 
Previous coronary artery bypass 
graft 
1.100 (1.060-1.141) <0.001 
Admission medication 
Clopidogrel 
Aspirin 
 
1.208 (1.159-1.259) 
1.029 (1.007-1.052) 
 
<0.001 
0.011 
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 Table S4. Sensitivity analysis of multivariate association between anemia and mortality in 
patients in whom baseline hemoglobin values were recorded 
 
Total cohort 
Mortality outcome N Odds ratio (95% CI) p-value 
Mortality at 30 days 254,999 1.530 (1.452-1.612) <0.001 
Mortality at 1 year 253,380 1.589 (1.535-1.645) <0.001 
Men only 
Mortality at 30 days 166,996 1.566 (1.458-1.681) <0.001 
Mortality at 1 year 165,901 1.698 (1.620-1.780) <0.001 
Women only 
Mortality at 30 days 88,003 1.479 (1.369-1.599) <0.001 
Mortality at 1 year 87,479 1.459 (1.38501.536) <0.001 
 
Bleeding excluded 
Mortality outcome N Odds ratio (95% CI) p-value 
Mortality at 30 days 249,901 1.524 (1.445-1.608) <0.001 
Mortality at 1 year 248,317 1.584 (1.529-1.641) <0.001 
Men only 
Mortality at 30 days 163,723 1.553 (1.444-1.671) <0.001 
Mortality at 1 year 162,648 1.684 (1.605-1.766) <0.001 
Women only 
Mortality at 30 days 86,170 1.481 (1.368-1.603) <0.001 
Mortality at 1 year 85,660 1.464 (1.389-1.542) <0.001 
  
Total cohort without imputations 
Mortality outcome N Odds ratio (95% CI) p-value 
Mortality at 30 days 
Unadjusted  
Fully adjusted 
 
254,999 
34,861 
 
2.905 (2.770-3.045) 
1.472 (1.197-1.810) 
 
<0.001 
<0.001 
Mortality at 1 year 
Unadjusted  
Fully adjusted 
 
253,380 
34,731 
 
3.072 (2.978-3.168) 
1.588 (1.430-1.763) 
 
<0.001 
<0.001 
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Figure S1. Flow chart of patient inclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total sample size 424,848 of MINAP cohort.  
• 257,999 participants with hemoglobin 
• 422,591 participants with mortality at 30 days 
• 420,430 participants with mortality at 1 year 
 
 
Total sample size 422,855 for each imputed dataset 
after imputations for all variables. 
Total sample size in anemia and relation to outcomes 
were: 
• 412,396 participants for mortality at 30 days 
• 410,301 participants with mortality at 1 year 
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Figure S2. Adjusted odds of mortality at 30 days according to hemoglobin levels and sex 
with exclusion of participants with bleed outcome 
 
 
 
  
